PCRX 株価分析 — PACIRA BIOSCIENCES, INC. (Healthcare >> Drug Manufacturers - Specialty & Generic)
PCRX に関するよくある質問
PCRXのPER(株価収益率)は?
PACIRA BIOSCIENCES, INC.(PCRX)は現在PER 106.28倍で取引されています。
PCRXのROE(自己資本利益率)は?
PACIRA BIOSCIENCES, INC.のROEは0.79%です。
PCRXの配当利回りは?
PACIRA BIOSCIENCES, INC.の配当利回りは0.00%です。
PCRXの品質スコア(Quality Score)は?
当社のAIはPCRXの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PCRXは今が買い時ですか?
当社AIのタイミングスコアは100点中87点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PCRXはどのセクターに属しますか?
PACIRA BIOSCIENCES, INC.はHealthcare >> Drug Manufacturers - Specialty & Genericセクターに分類されます(NASDAQ市場)
PCRX AI Analysis Summary
Our AI summary for PCRX: PACIRA BIOSCIENCES, INC. (NASDAQ), Healthcare >> Drug Manufacturers - Specialty & Generic sector. The stock currently trades at a P/E of 106.28, ROE of 0.79%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 26.41
Price
-0.56
(-2.08%)
Day Change
|
|
|---|
PCRX, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) but テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
P/Eが高い。割高銘柄。
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
44% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
3060
|
| Magic Formula Rank by ROE |
3060
|
| Magic Formula Rank by ROIC |
2945
|
| Price | 26.41 |
| PBV / Sector |
1.62 / 3.22
|
| Earning Per Share | 0.13 |
| PE / Sector |
106.28 / 29.79
|
| PEG or PE/Growth / Sector |
-0.94 / 0.13
|
| Average 1M Daily Value |
12.38 M
GREAT
|
| Average 1W Daily Value |
13.90 M
GREAT
|
| Timing Factors |
|
85% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:18 |
| Symbol | PCRX |
| Name | PACIRA BIOSCIENCES, INC. |
| Sector | Healthcare >> Drug Manufacturers - Specialty & Generic |
| Market | NASDAQ |
| Listed Shares | 39.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,061.21 / 10,754.62 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 2000 Sierra Point Parkway, Brisbane, CA, United States, 94005
Phone: 650 242 8052
Website: https://www.pacira.com
Employees: 825
Sector: Healthcare >> Drug Manufacturers - Specialty & Generic
Description: Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Drug Manufacturers - Specialty & Generic
Click a bubble to view stock details · Bubble size represents market capitalization share
Google